Innovent signs $10.5 billion Pfizer$10.5 billion Pfizer cancer drug trial deal
China’s Innovent Biologics said on May 29 that it has signed a deal worth up to US$10.5 billion with Pfizer to develop 12 cancer drug programmes.
The agreement covers co-development and co-commercialization in the United States and Europe, highlighting how major drugmakers are still pursuing cross-border partnerships despite wider geopolitical tensions.
- Cancer drug development is one of the most expensive areas in medicine, often taking many years and billions of dollars.
- Pfizer has frequently relied on partnerships to widen its reach in oncology, one of the industry's most competitive fields.
- China has become a major source of early-stage biotech research, even as global drug approvals still depend heavily on Western markets.
US-China Indo-Pacific Rivalry
China and Taiwan coast guard vessels have repeatedly faced off near the Pratas Islands, with the latest standoff showing how small maritime incidents around Taiwan can quickly become confrontations.[1][5] The episode adds to wider U.S.-China military tension across the Indo-Pacific, where Beijing is expanding patrols and Washington is reinforcing regional deterrence.[2][3] The rivalry now centers on preventing miscalculation around Taiwan, the South China Sea, and nearby sea lanes.[1][3][5] It also shapes defense planning by Taiwan, Japan, the Philippines, and the United States as all sides weigh coercion, sovereignty claims, and the risk of escalation.[2][3]
24 May, 07:39 AM
Taiwan and China coast guards face off near Pratas islands1 January
The United States adopts a sharper great-power competition strategy focused on China
